Clinical Trial Update: Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating ascorbate in combination with durvalumab for non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ascorbate (ascorbate)
• Durvalumab (durvalumab)

Snippet

Sponsor: William Zeitler | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: TERMINATED